
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) – Analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Eyepoint Pharmaceuticals in a report issued on Friday, November 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($3.64) per share for the year, down from their previous estimate of ($3.40). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q4 2026 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.43) EPS, Q4 2027 earnings at ($0.22) EPS and FY2027 earnings at ($1.56) EPS.
EYPT has been the topic of several other research reports. JPMorgan Chase & Co. lowered Eyepoint Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, October 20th. Chardan Capital downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target for the company. in a research note on Tuesday, August 18th. Laidlaw lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 20th. Guggenheim lowered Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, October 19th. Finally, Mizuho cut Eyepoint Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $0.50 price objective on the stock. in a research note on Tuesday, October 20th. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $21.85.
Eyepoint Pharmaceuticals Stock Performance
NASDAQ:EYPT opened at $0.27 on Tuesday. The stock’s 50-day simple moving average is $2.07 and its 200 day simple moving average is $10.03. The company has a market cap of $23.45 million, a P/E ratio of -0.07 and a beta of 1.84. Eyepoint Pharmaceuticals has a 52-week low of $0.27 and a 52-week high of $19.11.
Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.14). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.23 million. Eyepoint Pharmaceuticals had a negative return on equity of 168.83% and a negative net margin of 13,281.23%.
Institutional Investors Weigh In On Eyepoint Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC grew its holdings in Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares during the period. Aberdeen Group plc increased its position in Eyepoint Pharmaceuticals by 52.0% during the third quarter. Aberdeen Group plc now owns 3,053,945 shares of the company’s stock worth $9,986,000 after buying an additional 1,045,143 shares during the last quarter. Commodore Capital LP acquired a new position in Eyepoint Pharmaceuticals during the first quarter worth approximately $36,414,000. Hsbc Holdings PLC acquired a new position in Eyepoint Pharmaceuticals during the first quarter worth approximately $10,743,000. Finally, Stempoint Capital LP raised its stake in Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after buying an additional 456,915 shares during the period. 99.41% of the stock is owned by institutional investors.
Trending Headlines about Eyepoint Pharmaceuticals
Investors following EYPT have been watching these headlines:
- Positive Sentiment: HC Wainwright raised its FY2027 loss-per-share estimate to $1.56 from $1.84, suggesting a less severe projected loss. The firm nevertheless maintains a Neutral rating. MarketBeat analyst estimates
- Neutral Sentiment: A separate report cited an average analyst price target of $21.85, but the supplied coverage provides no details on the contributing estimates; the figure may not reflect the latest developments. Analyst price target report
- Negative Sentiment: HC Wainwright lowered its FY2026 loss-per-share estimate to $3.64 from $3.40 and sharply cut its Q3 2027 estimate, while keeping a Neutral rating. Those reductions point to weaker near-term earnings expectations. MarketBeat analyst estimates
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.
Featured Articles
- Five stocks we like better than Eyepoint Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
